Vanflyta Approved for FLT3-ITD Positive Acute Myeloid Leukemia
The FDA has approved Vanflyta (quizartinib) plus chemotherapy for adults with newly diagnosed AML that is FLT3-ITD positive.
Source: empr.com
Page 46 - Risk Evaluation News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Risk Evaluation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Risk Evaluation Today - Breaking & Trending Today
FDA Roundup: July 21, 2023
/PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA Center for...
Source: prnewswire.com
A state of conflicting laws
June 24 marked one year since the Supreme Court of the United States overturned Roe v. Wade, complicating abortion law in Wisconsin. Access to the nearby Twin Cities eases abortion
Source: hudsonstarobserver.com
VANFLYTA® First FLT3 Inhibitor Approved in the U.S. Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML
First and only FLT3 inhibitor approved across three phases of AML treatment based on QuANTUM-First results demonstrating VANFLYTA added to chemotherapy improved overall survival Third innovative...
Source: marketscreener.com
Wrap-Up of Federal and State Chemical Regulatory Developments, July 2023 | Bergeson & Campbell, P.C.
TSCA/FIFRA/TRI - EPA’s Spring 2023 Unified Agenda Includes Proposed And Final TSCA And TRI Rules: EPA’s spring 2023 Unified Agenda, published on June 13, 2023, includes a...
Source: jdsupra.com